Provided By GlobeNewswire
Last update: Feb 26, 2025
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 –
– Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures –
Read more at globenewswire.comNASDAQ:ASMB (6/23/2025, 4:30:01 PM)
17.1
-0.29 (-1.67%)
Find more stocks in the Stock Screener